InvestmentUpdated on 15 July 2025
Advanced Therapies for liver diseases
About
Liver fibrosis in the form of MASH is the most common liver disorder worldwide, will affect approximately 25% of world´s population (1 in 4)
TAM of 27 B
Currently, only one drug has received provisional FDA approval for MASH after 1 year of clinical trial. with some concerns: results after completion of the 5-year clinical trial / optimization of dosing and timing / long term safety / very expensive / not covered by Health Systems for a chronic treatment
But oru approach in totally new, Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that regulates the expression of multiple defensive genes.NRF2 makes heterodimers with small MAFs and activates genes containing the Antioxidant response Element (ARE).
Similar opportunities
Service
R&D and Clinical Genomic Services
- Development
- Cosmetic industry
- Laboratory industry
- Pharmaceutical industry
Marc del Pino
Southern Europe Sales Manager at GENEWIZ
Barcelona, Spain
Product
+270 Molecular Biology Reagents
- Distribution Partner
- Laboratory industry
- Pharmaceutical industry
Jesús C. Morales
Business Development Manager at Canvax Reagents S.L.
Valladolid, Spain
Service
Pre-clinical & Clinical Bioanalysis · GLP & GCP Compliant
- Development
- Manufacturing
- Cosmetic industry
- Laboratory industry
- Pharmaceutical industry
Xavier Martínez
BD Iberia at Kymos Group
Barcelona, Spain